CytomX Therapeutics
Market cap $423M 218.0M shares (10-Q, Oct 31, 2026) × $1.94 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- Varseta-M trial start2H 2026Varseta-M trial start, 2H 2026, notable
- CX-801 Ph1 readout1H 2027CX-801 Ph1 readout, 1H 2027, material
- CX-801 readout1H 2027CX-801 readout, 1H 2027, material
- Varseta-M (CX-2051) mCRC monotherapy PhaseJan 2027Varseta-M (CX-2051) mCRC monotherapy Phase, Jan 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
CX-801
CX-908
- Undisclosed indication
Varseta-M
varsetatug masetecanTechnology platforms
PROBODY
Conditionally activated, masked biologics platform leveraging tumor-associated proteases to unmask and preferentially activate drug candidates in the tumor microenvironment. Applied across multiple modalities including ADCs, T-cell engagers, and cytokines for oncology indications.
PROBODY · Regeneron
Biologic masking platform that produces conditionally activated, masked antibody-based therapeutics localized to the tumor microenvironment via protease activation; used for ADCs, cytokines, T-cell engagers, and bispecific antibodies in oncology
Discontinued (2)
- praluzatamab ravtansine — Breast Cancer · Phase 2 did not show required progression free survival; program deprioritized; CX-2009 License terminated in 2025
- CX-904 — undisclosed · jointly discontinued the program in March 2025
Capital (as filed)
- Cash
- $34.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $314M Sep 30, 2026
- Operating cash flow
- $16.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $348M cash, runway 2H 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-06 UPDATE: CytomX Therapeutics (CTMX) - The Market Is Pricing Varseta-M Near Zero
- 2026-08-27 UPDATE: CytomX Therapeutics (CTMX) - The FDA Puts Varseta-M on the Fast Lane 🔒 Paid
- 2026-08-07 UPDATE: CytomX Therapeutics (CTMX) - Two Partners Walked, One Doubled Down 🔒 Paid
- 2026-06-03 UPDATE: CytomX Therapeutics (CTMX) - Regeneron Doubles Down on the Mask 🔒 Paid
- 2026-04-18 UPDATE: CytomX Therapeutics (CTMX) - Act III of the Institutional Drama 🔒 Paid
- 2026-03-22 UPDATE: CytomX (CTMX) - Clears the Binary Hurdle and Executes the Classic Biotech Playbook 🔒 Paid
- 2026-01-28 CytomX Therapeutics (CTMX): Scientific Deep Dive for Varseta-M and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on CytomX Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-28 Watch CytomX Therapeutics (CTMX): Scientific Deep Dive for Varseta-M and Pipeline Products The EpCAM masking technology shows promise with a 28% ORR but the Grade 5 death and narrow therapeutic window make the Q1 2026 data readout a binary event requiring observation before committing capital.
- 2026-03-22 Speculative buy speculative UPDATE: CytomX (CTMX) - Clears the Binary Hurdle and Executes the Classic Biotech Playbook The Q1 data met and exceeded the green-light criteria (32% ORR, 7.1-month PFS, Grade 3 diarrhea down to 10%), retiring the binary toxicity risk, and the $250M raise clears the financing overhang, offering a de-risked entry point.
- 2026-04-18 Speculative buy speculative UPDATE: CytomX Therapeutics (CTMX) - Act III of the Institutional Drama Point72 building an 8.6% stake on the post-dilution reset confirms sophisticated capital is loading up on the de-risked clinical profile and fully funded balance sheet.
- 2026-06-03 Speculative buy speculative UPDATE: CytomX Therapeutics (CTMX) - Regeneron Doubles Down on the Mask Regeneron's expansion to ~$4B in potential milestones and $37M in immediate non-dilutive cash independently validates the PROBODY platform while the stock sits 39% below where sophisticated capital bought in, reconstituting asymmetry.
- 2026-08-07 Speculative buy speculative UPDATE: CytomX Therapeutics (CTMX) - Two Partners Walked, One Doubled Down Despite BMS and Astellas terminations elevating platform risk, the de-risked lead asset, $330M+ fortress balance sheet with runway to 2H 2028, registrational path with 1H 2027 start, and price 36% below where sophisticated capital bought still presents asymmetry.
- 2026-08-27 Speculative buy speculative UPDATE: CytomX Therapeutics (CTMX) - The FDA Puts Varseta-M on the Fast Lane FDA Fast Track Designation incrementally de-risks the regulatory path and signals agency alignment with the registrational strategy while the price remains flat and 35% below where sophisticated capital bought.
- 2026-11-06 Speculative buy speculative UPDATE: CytomX Therapeutics (CTMX) - The Market Is Pricing Varseta-M Near Zero At $2.14 with $348M cash covering ~74% of market cap, the market prices Varseta-M near zero ahead of the January 2027 readout, but the paused Regeneron program and repeated calendar slippage warrant sizing any new position as a lottery ticket.
- Long call · opened Mar 23, 2026 at $4.46 · -56.5% vs XBI +19.4% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (31)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseCytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
- Nov 5, 2026ReleaseCytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1 CYTOMX Q3 2026 EARNINGS RELEASE_DRAFT_POST_AC_FOR APPROVAL→ BD updateQ3 earnings confirm the dose-selection data readout slips to January 2027, BMS's termination is now on the books, and the stock has cratered 37% since the August Fast Track update — but $348M in cash and an expanding indication footprint say the thesis isn't broken, just delayed.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 2, 2026ReleaseCytomX Therapeutics to Present at Upcoming November Investor Conferences
- Oct 29, 2026ReleaseCytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
- Sep 1, 2026ReleaseCytomX Therapeutics to Present at Upcoming September Investor Conferences
- Aug 27, 2026ReleaseCytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)→ BD updateThe FDA just granted Fast Track Designation to Varseta-M in relapsed/refractory mCRC — the first formal regulatory signal on a drug the thesis has been building toward since the March data readout, and a meaningful de-risking step ahead of the planned 1H 2027 registrational study.
- Aug 6, 2026ReleaseCytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly report
- Aug 3, 2026ReleaseCytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
- Jul 30, 2026ReleaseCytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Jul 27, 2026ReleaseCytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
- Jul 27, 20268-KCurrent report: officer / director change
- Jun 22, 20268-KCurrent report: officer / director change, charter / bylaws / fiscal year, shareholder vote
- Jun 3, 2026ReleaseCytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
- Jun 3, 20268-KCurrent report: material agreement
- May 21, 2026ReleaseCytomX Therapeutics to Present at Upcoming June Investor Conferences
- May 18, 2026ReleaseCytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
- May 7, 2026ReleaseCytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 30, 2026DEFA14AProxy soliciting material
- Apr 30, 2026DEF 14AProxy statement
- Mar 19, 20268-KCurrent report: other events
- Mar 18, 2026424B5Prospectus supplement (offering)
- Mar 16, 2026S-3ASRAutomatic shelf registration
- Mar 16, 20268-KCurrent report: results of operations · EX-99.1
- Mar 16, 2026424B5Prospectus supplement (offering)
- Mar 16, 202610-KAnnual report
17 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Oct 28, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 6, 2026S-8Employee plan registration
- Aug 3, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 20, 2026PRE 14APRE 14A
- Apr 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 26, 2026SCHEDULE 13G/A13G amendment
- Mar 4, 2026SCHEDULE 13GPassive >5% holder (13G)